How to buy Precigen stock (PGEN)

Precigen is a biotechnology business based in the US. Precigen shares (PGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.76 – an increase of 12.93% over the previous week. Precigen employs 202 staff and has a trailing 12-month revenue of around $4.4 million.

Our top picks for where to buy Precigen stock

Buy Precigen stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Precigen stock price (NASDAQ: PGEN)

Use our graph to track the performance of PGEN stocks over time.

Precigen shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$0.76
52-week range	$0.65 - $1.93
50-day moving average more info button	$0.85
200-day moving average more info button	$1.23
Wall St. target price	$6.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.54

Is it a good time to buy Precigen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Precigen price performance over time

Historical closes compared with the close of $0.7258 from 2024-12-19

1 week (2024-12-13)	7.48%
1 month (2024-11-21)	-19.61%
3 months (2024-09-20)	-27.06%
6 months (2024-06-21)	-52.87%

1 year (2023-12-21)	-35.77%
2 years (2022-12-21)	-50.63%
3 years (2021-12-21)	3.97
5 years (2019-12-20)	5.74

Precigen financials

Revenue TTM	$4.4 million
Gross profit TTM	$20.6 million
Return on assets TTM	-42.32%
Return on equity TTM	-129.32%
Profit margin	0%
Book value	$0.48
Market Capitalization more info button	$208.7 million

TTM: trailing 12 months

Precigen share dividends

We're not expecting Precigen to pay a dividend over the next 12 months.

Precigen share price volatility

Over the last 12 months, Precigen's shares have ranged in value from as little as $0.6513 up to $1.93. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Precigen's is 1.682. This would suggest that Precigen's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Precigen overview

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications.

Frequently asked questions

What percentage of Precigen is owned by insiders or institutions?
Currently 10.175% of Precigen shares are held by insiders and 63.826% by institutions. How many people work for Precigen?
Latest data suggests 202 work at Precigen. When does the fiscal year end for Precigen?
Precigen's fiscal year ends in December. Where is Precigen based?
Precigen's address is: 20358 Seneca Meadows Parkway, Germantown, MD, United States, 20876 What is Precigen's ISIN number?
Precigen's international securities identification number is: US74017N1054 What is Precigen's CUSIP number?
Precigen's Committee on Uniform Securities Identification Procedures number is: 74017N105